Nephrology sponsored testing program 

Invitae partners with biopharma companies to offer sponsored testing for patients who meet eligibility criteria

Alnylam Act® Primary Hyperoxaluria Type 1

Primary Hyperoxaluria Type 1

Invitae and Alnylam have partnered to offer genetic testing at no charge for individuals who may carry a gene mutation known to be associated with primary hyperoxaluria type 1.

The Alnylam Act program was created to potentially enable diagnosis and to provide genetic counseling to help people make more informed decisions about their health.

KIDNEYCODE

Unlock the underlying cause of CKD with genetic testing. Reata Pharmaceuticals and Invitae have partnered to offer sponsored, no-charge genetic testing and counseling for patients with chronik kidney disease (CKD) to facilitate diagnosis of several rare forms of CKD, including Alport syndrome, FSGS, and one form of ADPKD (PKD2).

By providing precise genetic information, KIDNEYCODE can help guide important, often time-sensitive health decisions for patients at risk for progressive CKD.